Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma
نویسندگان
چکیده
John E. Janik, John C. Morris, Deirdre O’Mahony, Stefania Pittaluga, Elaine S. Jaffe, Christophe E. Redon, William M. Bonner, Martin W. Brechbiel, Chang H. Paik, Millie Whatley, Clara Chen, Jae-Ho Lee, Thomas A. Fleisher, Maggie Brown, Jeffrey D. White, Donn M. Stewart, Suzanne Fioravanti, Cathryn C. Lee, Carolyn K. Goldman, Bonita R. Bryant, Richard P. Junghans, Jorge A. Carrasquillo, Tat’Yana Worthy, Erin Corcoran, Kevin C. Conlon, and Thomas A. Waldmann
منابع مشابه
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
Despite significant advances in the treatment of Hodgkin's lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for systemic radioimmunotherapy of HL. The scientific basis for the clinical trial was that, although most normal cells with exception of Treg cells do not express ...
متن کاملMonoclonal antibody therapy for classical Hodgkin lymphoma
8531 (2009). Monoclonal antibody therapy for classical Hodgkin lymphoma Review: Clinical Trial Outcomes future science groupClin. Invest. (2013) 3(9)90932 Thertulien R, Frankel AE, Evens AM et al. APhase I, open-label, dose-escalation,multidose study of MDX-1401 (defucosylatedhuman antiCD30 monoclonal antibody) inpatients with CD30-positive refractory/relapsed Ho...
متن کاملStudy of the ratio of Treg/Th1 and Treg/Th2 lymphocytes in Hodgkin's lymphoma patients and its relationship with disease prognosis
Background and purpose: CD4+CD25+FOXP3+ regulatory T cells (CD4+CD25+FOXP3+ Tregs) are a group of T lymphocytes that play an important role in regulating immune system responses by suppressing the activity of other T cells and establishing homeostasis in the immune system. Th1 and Th2 cells are other groups of CD4+ cells that play important functions in inducing inflammatory immune responses. C...
متن کاملTreatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development
Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy with biological agents, such as the immunotoxin gemtuzumab ozog...
متن کاملMonoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin’s Lymphoma (NHL)
Copyright: © 2013 Uckun FM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. In recent years new biotherapy options have emerged for patients with B-lineage Non-Hodgkin’s Lymphoma (NHL). A series of novel mAbs ...
متن کامل